Nitric Oxide Therapy for Acute Chest Syndrome in Sickle Cell Disease Children

Clinical Trial
Study Details
Enrollment
21
Interventions
Description

Nitric oxide by inhalation INOMAX 800 ppm

40 ppm during 24 hours then 20 ppm during 24 hours then 10 ppm during 24 hours

Name
Nitric oxide by inhalation INOMAX
Type
Drug
Description

placebo

Name
Placebo
Type
Drug
Phase
Phase 2
Status
COMPLETED
Study ID #
NCT01089439
Study Type
Interventional
Summary

Acute chest syndrome is a severe sickle cell disease complication in children requiring blood transfusion therapy to prevent acute respiratory failure and death. Nitric oxide is a potent vasodilator that could reverse pulmonary vascular occlusion and restore normal oxygenation. The randomized trial will test that hypothesis.

Study Overview
Description

Acute chest syndrome is a severe sickle cell disease complication in children requiring blood transfusion therapy to prevent acute respiratory failure and death. Nitric oxide is a potent vasodilator that could reverse pulmonary vascular occlusion and restore normal oxygenation. The randomized trial will test that hypothesis in a prospective randomized double-blind placebo controlled study. 50 children in two years will be included: 25 in each arm.

Contacts and Locations
Locations
Facility

Hoipital Robert Debre
75019 Paris
France

GeoPoint
48.85341, 2.3488